Blocking Costimulatory Signals to Induce Transplantation Tolerance and Prevent Autoimmune Disease

References

• Pattison J., Sibley R., Krensky A. Mechanisms of Allograft Rejection. Immunologic Renal Disease, 1st ed., E. Neilson, W. Couser. Lippincott-Raven Publishers, Philadelphia 1997; 331–354
   Google Scholar
• Sayegh M. H., Watschinger B., Carpenter C. B. Mechanisms of T cell recognition of alloantigen: the role of peptides. Transplantation 1994; 57: 1295
   PubMed Web of Science ®Google Scholar
• Janeway C. H., Bottomly K. Signals and signs for lymphocyte responses. Cell 1994; 76: 275–285
   PubMed Web of Science ®Google Scholar
• June C. H., Bluestone J. A., Nadler L. M., Thompson C. B. The B7 and CD28 receptor families. Immunology Today 1994; 15(7)321–331
   PubMedGoogle Scholar
• June C. H., Ledbetter J. A., Linsley P. S., Thompson C. B. Role of the CD28 receptor in T cell activation. Immunol. Today 1990; 11: 211–216
   PubMedGoogle Scholar
• Linsley P. S., Ledbetter J. A. The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 1993; 11: 191–221
   PubMed Web of Science ®Google Scholar
• Jenkins M. K., Ashwell J. D., Schwartz R. H. Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells. J. Immunol. 1987; 140: 3324–3330
   Google Scholar
• Freeman G. J., Borriello F., Hodes R. J., Reiser H., Gribben J. G., Ng J. W., Kim J., Goldberg J. M., Hathcock K. S., Laszlo G., Lombard D. B., Wang S., Gray G. S., Nadler L. M., Sharpe A. H. Murine B7–2, an alternative CTLA4 couter-recptor that costimulates T cell proliferation and interleukin 2 production. J. Exp. Med. 1993; 178: 2185–2192
   PubMed Web of Science ®Google Scholar
• Linsley P. S., Brady W., Urnes M., Grosmaire L. S., Damle N. K., Ledbetter J. A. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 1991; 174: 561–569
   PubMed Web of Science ®Google Scholar
• Linsley P., Clark E., Ledbetter J. T cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc. Natl. Acad. Sci. USA 1990; 87: 5031–5035
   PubMed Web of Science ®Google Scholar
• Hathcock K., Laszio G., Pucillo C., Linsley P., Hodes R. Comparative analysis of B7–1 and B7–2 costimulatory ligands: Expression and function. J. Exp. Med. 1994; 180: 631–640
   PubMed Web of Science ®Google Scholar
• Kuchroo V. K., Das D. P., Brown J. A., Ranger A. M., Zamvil S. S., Sobel R. A., Werner H. L., Nabavi N., Glimcher L. H. B7–1 and B7–2 costimulatory molecules activate differentially the Th1/Th2 development pathways: application to autoimmune disease therapy. Cell 1995; 80(5)707–718
   PubMed Web of Science ®Google Scholar
• Walunas T. L., Bakker C. Y., Bluestone J. A. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 1996; 183: 2541–2550
   PubMed Web of Science ®Google Scholar
• Krummel M. F., Allison J. P. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 1996; 183: 2533–2540
   PubMed Web of Science ®Google Scholar
• Tivol E. A., Boriello F., Schweitzer A. M., Lynch W. P., Bluestone J. A., Sharpe A. H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3: 541–547
   PubMed Web of Science ®Google Scholar
• Waterhouse P., Penninger J. M., Timms E., Wakeham A., Shahinian A., Lee C. B., Thompson C. B., Griesser H., Mak T. W. Lymphoproliferative disorders with early lethality in mice deficient in CTLA4. Science 1995; 270: 985–988
   PubMed Web of Science ®Google Scholar
• Tivol E., Boyd S., McKeon S., Borriello F., Nickerson P., Strom T., Sharpe A. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J. Immunol. 1997; 158: 5091–5094
   PubMed Web of Science ®Google Scholar
• Lenschow D., Zeng Y., Thistlethwaite R., Montag A., Brady W., Gibson P. S., Linsley P. S., Bluestone J. A. Long-term survival of xenogeniec pancreatic islet grafts induced by CTLA4Ig. Science 1992; 257: 789–792
   PubMed Web of Science ®Google Scholar
• Turka L. A., Linsley P. S., Lin H., Brady W., Leiden J. M., Wei R. Q., Gibson X. G., Zheng X. G., Myrdal S., Gordon D., Bailey T., Boiling S. F., Thompson C. B. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc. Natl. Acad. Sci. USA 1992; 89: 11102–11105
   PubMed Web of Science ®Google Scholar
• Lin H., Boiling S. F., Linsley P. S., Wei R. Q., Gordon D., Thompson C. B., Turka L. A. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J. Exp. Med. 1993; 178: 1801–1806
   PubMed Web of Science ®Google Scholar
• Sayegh M. H., Turka L. A. T cell costimulatory pathways: Promising novel targets for immunosuppression and tolerance induction. J. Am. Soc. Nephrol. 1995; 6: 1143–1150
   PubMed Web of Science ®Google Scholar
• Hancock W. W., Sayegh M. H., Zheng X. G., Peach R., Linsley P. S., Turka L. A. Costimulatory function and expression of CD40-ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc. Natl. Acad. Sci. USA 1996; 93: 13967–13972
   PubMed Web of Science ®Google Scholar
• Perez V., Parijs L. V., Biuckians A., Zheng X., Strom T., Abbas A. Induction of peripheral T cell tolerance in vivo required CTLA-4 engagement. Immunity 1997; 6: 411–417
   PubMed Web of Science ®Google Scholar
• Pearson T. C., Alexander D. Z., Hendrix R., Elwood E. T., Linsley P. S., Winn K. J., Larsen C. P. CTLA4Ig plus bone marrow induces long-term allograft survival and donor-specific unresponsiveness in the murine model. Transplantation 1996; 61: 997–1004
   PubMed Web of Science ®Google Scholar
• Sayegh M., Zheng X. G., Magee C., Hancock W., Turka L. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allografts. Transplantation 1997; 64: 1646–1650
   PubMed Web of Science ®Google Scholar
• Russell M. E., Hancock W. W., Akalin E., Wallace A. F., Glysing-Jensen T., Willett T., Sayegh M. H. Chronic cardiac rejection in the Lewis to F344 rat model: Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J. Clin. Invest. 1996; 97: 833–838
   Google Scholar
• Sayegh M. H., Akalin E., Hancock W. W., Russell M. E., Carpenter C. B., Turka L. A. CD28-B7 blockade after alloantigenic challange in vivo inhibits Th1 cytokines but spares Th2. J. Exp. Med. 1995; 181: 1869–1874
   PubMed Web of Science ®Google Scholar
• Austyn J. M., Hankins D. F., Larsen C. P., Morris P. J., Rao A. S., Roake J. A. Isolation and characterization of dendritic cells from mouse heart and kidney. J. Immunol. 1994; 152: 2401–2410
   PubMedGoogle Scholar
• Lenschow D. J., Zeng Y., Hathcock K. S., Zuckerman L. A., Freeman G., Thistlethwaite J. R., Gray G. S., Modes R. J., Bluestone J. A. Inhibition of transplant rejection following treatment with anti-B7–2 and anti-B7-l antibodies. Transplantation 1995; 60: 1171–1178
   PubMedGoogle Scholar
• Zheng X., Sayegh M., Zheng X. G., Linsley P., Peach R., Borriello F., Strom A., Sharpe A., Turka L. The role of donor and recipient B7–1 (CD80) in allograft rejection. J. Immunol. 1997; 159: 1169–1173
   Google Scholar
• Durie F. H., Foy T. M., Masters S. R., Laman J. D., Noelle R. J. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunology Today 1994; 15: 406–411
   PubMedGoogle Scholar
• Parker D. C., Greiner D. L., Philips N. E., Appel M. C., Steele A. W., Durie R. J., Noelle R. J., Mordes J. P., Rossini A. A. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc. Natl. Acad. Sci. USA 1995; 92: 9560–9564
   PubMed Web of Science ®Google Scholar
• Larsen C. P., Alexander D. Z., Hollenbaugh D., Elwood E. T., Ritchie S. C., Aruffo A., Hendrix R., Pearson T. C. CD40-gp39 interactions play a critical role during allograft rejection: suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation 1996; 61: 4–9
   PubMed Web of Science ®Google Scholar
• Kirk A. D., Harlan A. M., Armstrong N. N., Davis T. A., Dong Y., Gray G. S., Hong X., Thomas D., Fechner J. H., Jr., Knechtle S. J. CTLA4Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. USA 1997; 94: 8789–8794
   PubMed Web of Science ®Google Scholar
• Larsen C. P., Elwood E. T., Alexander D. Z., Ritchie S. C., Hendrix R., Tucker-Burden C., Cho H. R., Aruffo A., Hollenbaugh D., Linsley P. S., Winn K. J., Pearson T. C. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434–438
   PubMed Web of Science ®Google Scholar
• Grewal I. S., Foellmer H. G., Grewal K. D., Xu J., Hardardottir F., Baron J. L., Janeway C. A., Jr., Flavell R. A. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science 1996; 273: 1864–1867
   PubMed Web of Science ®Google Scholar
• Yang Y., Wilson J. M. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science 1996; 273: 1862–1864
   PubMed Web of Science ®Google Scholar
• Finck B. K., Linsley P. S., Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994; 265: 1225–1227
   PubMed Web of Science ®Google Scholar
• Nishikawa K., Linsley P. S., Collins A. B., Stamenkovic I., McCluskey R. T., Andres G. Effect of CTLA-4 chimeric protein on rat autoimmune anti-glomerular basement membrane glomerulonephritis. Eur. J. Immunol. 1994; 24: 1249–1254
   PubMed Web of Science ®Google Scholar
• Cross A. H., Girard T. J., Giacoletto K. S., Evans R. J., Keeling R. M., Lin R. F., Trotter J. L., Karr R. W. Long-term inhibition of murine experimental autoimmune encephalomyelitis. Using CTLA4-Fc supports a key role for CD28 costimulation. J. Clin. Invest. 1995; 95: 2783–2789
   PubMed Web of Science ®Google Scholar
• Kuchroo V. K., Das M. P., Brown J. A., Ranger A. M., Zamvil S. S., Sobel R. A., Nabavi N., Weiner H. L., Glimcher L. H. B7–1 and B7–2 costimulatory molecules differentially activate the TH1/TH2 developmental pathways: Application to autoimmune disease therapy. Cell 1995; 80: 707–718
   PubMed Web of Science ®Google Scholar
• Perrin P. J., Scott D., Quigley L., Albert P. S., Feder O., Gray G. S., Abe R., June C. H., Racke M. K. Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. J. Immunol. 1995; 154: 1481–1490
   PubMed Web of Science ®Google Scholar
• Racke M. K., Scott D. E., Quigley L., Gray G. S., Abe R., June C. H., Perrin P. J. Distinct roles for B7–1 (CD-80) and B7–2 (CD-86) in the initiation of experimental allergic encephalomyelitis. J. Clin. Invest. 1995; 96: 2195–2203
   PubMed Web of Science ®Google Scholar
• Khoury S. J., Akalin E., Chandraker A., Turka L. A., Linsley P. S., Sayegh M. H., Hancock W. W. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J. Immunol. 1995; 155: 4521–4524
   PubMed Web of Science ®Google Scholar
• Arima T., Rehman A., Hickey W. F., Flye M. W. Inhibition by CTLA4Ig of experimental allergic encephalomyelitis. J. Immunol. 1996; 156: 4916–4924
   PubMed Web of Science ®Google Scholar
• Lenschow D. J., Ho S. C., Sattar H., Rhee L., Gray G., Nabavi N., Herold K. C., Bluestone J. A. Differential effects of anti-B7-l and anti-B7–2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 1995; 181: 1145–1155
   PubMed Web of Science ®Google Scholar
• Miller S. D., Vanderlugt C. L., Lenschow D. J., Pope J. G., Karandikar N. J., DalCanto M. C., Bluestone J. A. Blockade of CD28/B7–1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity 1995; 3: 739–745
   PubMed Web of Science ®Google Scholar
• Harris N., Peach R., Naemura J., Linsley P. S., Gros G. L., Ronchese F. CD80 costimulation is essential for the induction of airway eosinophilia. J. Exp. Med. 1997; 185: 177–182
   PubMed Web of Science ®Google Scholar
• Gallon L., Chandraker A., Issazadeh S., Peach R., Linsley P. S., Turka L. A., Sayegh M. H., Khoury S. J. Differential effects of B7–1 blockade in the rat experimental autoimmune encephalomyelitis model. J. Immunol. 1997; 159: 4212–4216
   Google Scholar
• Azuma M., Yssel H., Phillips J. H., Spits H., Lanier L. L. Functional expression of B7/BB1 on activated T lymphocytes. J. Exp. Med. 1993; 177: 845
   PubMed Web of Science ®Google Scholar
• PrabhuDas M. R., Zamvil S. S., Borriello F., Weiner H. L., Sharpe A. H., Kuchroo V. K. Reciprocal expression of co-stimulatory molecules, B7–1 and B7–2, on murine T cells following activation. Eur. J. Immunol. 1995; 25: 207–211
   Google Scholar
• Krummel M. F., Allison J. P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation (see comments). J. Exp. Med. 1995; 182(2)459–465
   PubMed Web of Science ®Google Scholar
• Walunas T. L., Lenschow D. J., Bakker C. Y., Linsley P. S., Freeman G. J., Green J. M., Thompson C. B., Bluestone J. A. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1: 405–413
   PubMed Web of Science ®Google Scholar
• Perrin P. J., Maldonado J. H., Davis T. A., June C. H., Racke M. K. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J. Immunol. 1996; 157: 1333–1336
   PubMed Web of Science ®Google Scholar
• Karandikar N. J., Vanderlugt C. L., Walunas T. L., Miller S. D., Bluestone J. A. CTLA-4: a negative regulator of autoimmune disease. J. Exp. Med. 1996; 184: 783–788
   PubMed Web of Science ®Google Scholar
• Hurwitz A. A., Sullivan T. J., Krummel M. F., Sobel R. A., Allison J. P. Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J. Neuroimmunol. 1997; 73: 57–62
   PubMed Web of Science ®Google Scholar
• Hirokawa M., Kitabayashi A., Kuroki J., Miura A. B. Signal transduction by B7/BB1 expressed on activated T lymphocytes: cross-linking of B7/BB1 induces protein tyrosine phosphorylation and synergizes with signalling through T-cell receptor/CD3. Immunology 1995; 86: 155–161
   Google Scholar
• Khoury S. J., Gallon L., Verburg R. R., Chandraker A., Peach R., Linsley P. S., Turka L. A., Hancock W. W., Sayegh M. H. Ex vivo treatment of antigen presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat. J. Immunol. 1996; 157: 3700–3705
   PubMed Web of Science ®Google Scholar
• Jenkins M. K., Schwartz R. H. Antigen-presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 1987; 165: 302–319
   PubMed Web of Science ®Google Scholar
• Miller S. D., Wetzig R. P., Claman H. N. The induction of cell-mediated immunity and tolerance with protein antigens coupled to syngeneic lymphoid cells. J. Exp. Med. 1979; 149: 758
   PubMed Web of Science ®Google Scholar
• Steurer W., Nickerson P. W., Steele A. W., Steiger J., Zheng X. X., Strom T. B. Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance. J. Immunol. 1995; 155: 1165–1174
   PubMed Web of Science ®Google Scholar
• Zitvogel L., Mayordomo J. I., Tjandrawan T., DeLeo A. B., Clarke M. R., Lotze M. T., Storkus W. J. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 1996; 183: 87–97
   PubMed Web of Science ®Google Scholar
• Gerritse K., Laman J. D., Noelle R. J., Aruffo A., Ledbetter J. A., Boersma W. J., Claassen E. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Nat J. Acad. Sci. USA 1996; 93: 2499–2504
   PubMed Web of Science ®Google Scholar
• Durie F. H., Fava R. A., Foy T. M., Aruffo A., Ledbetter J. A., Noelle R. J. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993; 261: 1328–1330
   PubMed Web of Science ®Google Scholar
• Early G. S., Zhao W., Burns C. M. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J. Immunol. 1996; 157: 3159–3164
   PubMed Web of Science ®Google Scholar
• Mohan C., Shi Y., Laman J. D., Datta S. K. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J. Immunol. 1995; 154: 1470–1480
   PubMed Web of Science ®Google Scholar
• Schaub M., Chandraker A., Sayegh M. H., Khoury S. J. Synergistic effect of CD40L/CD40 and Cd28/B7 blockade in murine EAE. Neurol 1997; 48(Suppl.)A420–421
   Google Scholar